



Medicines Patent Pool Governance Board Meeting #33

May 3rd, 2022
Virtual meeting

Attendees

Governance Board Members:

Marie-Paule Kieny (Chair), Mojisola Christianah Adeyeye, Manica Balasegaram, Patrizia Carlevaro, Jinliang Li, Peter Maybarduk, John-Arne Røttingen, Maximiliano Santa Cruz.

Excused Board Members:

Alexandra Volgina

Non-voting members:

Peter Beyer – EAG Chair; Jan Akko Eleveld – Unitaaid Project Team; Katherine Hencher – Unitaaid Executive Team; Robert Matiru - Unitaaid Executive Team; Karin Timmermans – Unitaaid Strategy Team; Marion (Amy) Dietterich – WIPO Observer; Antony Scott Taubman – WTO Observer.

Excused non-voting participants:

Mariângela Batista Galvão Simão – WHO Observer

Medicines Patent Pool Foundation Management Team:

Charles Gore – Executive Director; Karine Belondrade – Head of Strategy, Operations and Resource Mobilisation; Esteban Burrone – Head of Policy; Vincent Chauvin – CFO, Head of Human Resources; Ruth Foley – Monitoring and Evaluation Manager; Ike James – Head of Technology Transfer; Muriel Lacombe – Finance and Administration Manager; Gelise McCullough – Head of Communications; Sandra Nobre – Head of Business Development; Chan Park – General Counsel; and Agnese Tonnina – Grants and Operations Manager.

Auditors:

Marie-Charlotte Burnet
Anne-Céline Bosviel

Summary of Decisions

The Governance Board of the Medicines Patent Pool:

1. Approves the agenda of the Governance Board Meeting #33.
2. Approves the strategy for communicating on aspects of MPP's licence negotiations presented by the Management and requests that the draft viewpoint article be shared with the Board before its publication.
3. Approves postponing a more in-depth exploration of the diagnostics field for the next 18 months. During that period, opportunities for intervention will be reviewed by the Strategy and Partnerships Committee on a case-by-case basis.
4. Approves all the changes resulting from the Management review of the risk register, including the integration of the SA mRNA Technology Transfer Hub risks for which MPP is accountable together with WHO and the creation of the overarching Risk 48.
5. Approves the *Access to Medicines Expert* and *Business Strategy Expert* profiles and the timeline for the recruitment of existing and new Board positions.
6. Approves the creation of the Community Advisory Panel (CAP) and agrees that both the CAP and the existing Scientific Advisory Panel (SAP) will be entirely under the purview of the Executive Director. As such, decisions about these panels will be made by the Executive Director moving forward.
7. Approves the 2021 financial statements and the auditors' report.
8. Approves the Operational KPI Framework 2021 Results Report, including the 2022 target adjustments for KPIs 2.1, 2.2 and 2.3 as proposed.